Table 3.
Side effects of PCSK9 inhibitor therapy reported by patients, cause of therapy adjustments and discontinuation
| Adverse effect documented in patients record | |
| Joint or muscle pain | 10 |
| Rhinitis | 5 |
| Flu-like symptoms | 5 |
| Fatigue | 4 |
| Skin lesions or pruritus | 4 |
| Gastrointestinal symptoms | 2 |
| Insomnia | 1 |
| Elevated insulin requirements | 1 |
| Cause leading to PCSK9 inhibitor therapy adjustment (switch of PCSK9 inhibitor agent) | |
| Adverse effect | 8 |
| Joint or muscle pain | 6 |
| Flu-like symptoms | 3 |
| Fatigue | 1 |
| Gastrointestinal symptoms | 1 |
| Dose reduction (evolocumab 140 mg to alirocumab 75 mg) | 1 |
| Cause leading to PCSK9 inhibitor therapy discontinuation | |
| Adverse effect | 7 |
| Joint or muscle pain | 3 |
| Skin lesions or pruritus | 2 |
| Gastrointestinal symptoms | 1 |
| Adverse effects not specified | 1 |
| Elevated insulin requirement | 1 |
| Non-responder (clearly documented) | 1 |
| Reasons of insurance coverage | 1 |
| By patient’s request | 1 |
Data are number of patients. Patients could have more than one symptom